We aimed at determining whether any association exists between genetic polymorphisms in epoxide hydrolase (EPHX1), NADPH-quinone oxidoreductase (NQO1), glutathione S-transferases (GSTM1/P1/T1) and individual susceptibility to breast cancer. Polymerase chain reaction-restriction fragment length polymorphism-based genotyping assays were used to determine the frequency of polymorphisms in EPHX1 (exons 3 and 4), NQO1 (exon 6), GSTM1 (deletion), GSTP1 (exon 5), and GSTT1 (deletion) in a case -control study comprised of 238 patients with breast cancer and 313 healthy individuals. The distribution of genotypes in exon 6 of NQO1 was significantly different between the control group and breast cancer cases. Age-adjusted odds ratio (OR) for variant genotype NQO1*2/*2 was 3.68 (confidence interval (CI) ¼ 1.41 -9.62, P ¼ 0.008). Association of GSTP1*2/*2 genotype as well as that of low EPHX1 activity deduced by combinations of genotypes in exons 3 and 4 with breast cancer was suggestive, but nonsignificant. Individuals simultaneously lacking GSTM1 and carrying at least one GSTP1 variant allele were at significantly higher risk of breast cancer (OR ¼ 2.03, CI ¼ 1.18 -3.50, P ¼ 0.010). Combinations of either GSTM1null or GSTP1*2 with low activity of EPHX1 presented significant risk of breast cancer (OR ¼ 1.88, CI ¼ 1.00 -3.52, P ¼ 0.049 and OR ¼ 2.40, CI ¼ 1.15 -5.00, P ¼ 0.019, respectively) as well. In conclusion, the results suggest that genetic polymorphisms in biotransformation enzymes may play a significant role in the development of breast cancer.
Introduction
Breast cancer is the most common malignancy and cause of death in the Western world. If current breast cancer rates remain constant, a woman born today has a one in 10 chance of developing breast cancer. 1 High-penetrance genes account for only 5% of cases, whereas polymorphic low-penetrance genes acting in concert with lifestyle/ environmental risk factors are likely to account for a much higher proportion.
Our study aimed at determining whether any association exists between genetic polymorphisms in EPHX1, NQO1, GSTM1, GSTP1, GSTT1 and individual susceptibility to breast cancer. For this study, we have chosen enzymes with relevance to metabolism of environmental contaminants and polymorphisms with known effect on protein expression, activity, and affinity.
The genetically variable biotransformation enzymes: epoxide hydrolase (EPHX1, EC 3.3.2.3), NAD(P)H:quinone oxidoreductase (NQO1, EC 1.6.99.2), and glutathione S-transferases (GST, EC 2.5.1.18) metabolize and conjugate drugs, carcinogens, and natural products. 2 In addition, high number of human cancer cases result from exposure to environmental carcinogens, 3 suggesting that individual effectiveness in the detoxification of these chemicals may influence susceptibility to malignant disease. EPHX1 catalyzes the hydrolysis of epoxides to lessreactive trans-dihydrodiols. 4 The absence of genetic complexity of EPHX1, located on chromosome 1 (1q42.1), is in striking contrast with other biotransformation enzymes. Two common alleles of EPHX1 can be detected by their mutations in exon 3 (site T337C, amino-acid change Tyr113His, allele nomenclature EPHX1*1/*3) and exon 4 (A415G, His139Arg, EPHX1*1/*4), which confer slow and fast enzyme activity, respectively. 5 The EPHX1*3/*3 genotype was associated with a decreased risk of invasive ovarian cancer of the endometrioid subtype.
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NQO1 gene located on chromosome 16 (16q22.1) encodes an obligate two-electron reductase that can either bioactivate or detoxify quinones and has been proposed to play an important role in chemoprevention. 7 The polymorphism in exon 6 of NQO1 (C609T, Pro187Ser, NQO1*1/ *2) was associated with the risk of colorectal cancer 8 and myeloid leukemia. 9 The case -control study of Hamajima et al 10 on Japanese suggested that the variant NQO1*2/*2 genotype increased the risk of cancers of the esophagus and lung but not breast. Siegelmann-Danieli and Buetow
11
published that NQO1 polymorphism might affect the histology development of breast tumors. GSTs are responsible for the detoxification of many carcinogens. GSTM1 is located on chromosome 1 (1p13.3), and meta-analysis of epidemiological studies showed that GSTM1 deficiency caused by homozygous deletion of the gene (null or GSTM1*2/*2 genotype) confers an increased risk of lung cancer. 12 Another gene deletion at the GSTT1 locus (22q11.2, null or GSTT1*2/*2 genotype) was reported by Pemble et al. 13 The GSTM1null genotype was significantly associated with breast cancer risk in postmenopausal women 14 but quite opposite finding was also published, that is, increased risk for premenopausal women.
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GSTP1, located on chromosome 11 (11q13), is overexpressed in some tumors and drug resistant cell lines, which may imply its role as a significant factor in acquired resistance to certain anticancer drugs. Board et al 16 identified two GSTP1 polymorphisms in exon 5 (A313G, Ile105Val, GSTP1*1/*2) and exon 6 (A342G, Ala114Val, GSTP1*1/*3). It was shown that the GSTP1 allelic variants generate enzymes with different heat stability and substrate affinity. 17 Women with the low-activity GSTP1*2/*2 genotype had better survival after breast cancer chemotherapy. 18 Genotyping Genomic DNA was isolated from peripheral lymphocytes by the phenol/chloroform extraction method described by Sugimura et al. 19 Genotypes of biotransformation enzymes were assayed with previously published PCR-restriction fragment length polymorphism (RFLP)-based methods.
Materials and methods

Materials
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Statistical analysis
In the first round of statistical analyses, we have tested differences in distribution of genotypes between cases and controls by Pearson w 2 test (asymptotic significance two-sided, df ¼ 2) and calculated crude odds ratios (ORs) from 2 Â 2 tables by the Mantel -Haenszel statistics (unconditional, df ¼ 1). Age-adjusted ORs were calculated using binary logistic regression by the Hosmer and Lemeshow test with profile likelihood based 95% confidence intervals (CI). Then, we analyzed prevalence of selected combinations of genotypes as follows:
, and GSTP1 þ NQO1. The selection of these combinations was based on hypothesis that carrier of at least one variant allele in both combined genes may be at higher risk and thus no correction was applied for multiple testing. For all statistic analyses, Win SPSS v10.0 program (SPSS Inc., Chicago, IL, USA) was used. When group size was less than 40 or when expected values in contingency tables were less than five, Fisher's exact test was used. The P-value lower than 0.05 was considered significant.
Results and discussion
Analysis of the distribution of genetic polymorphisms of biotransformation enzymes in cases and controls The results obtained are summarized in Table 1 . The observed frequencies and genotype distributions in our control group did not differ significantly from data on the majority of other European Caucasian subpopulations. 20 Most interesting result was obtained by analysis of distribution of genotypes in NQO1-exon 6. Both the difference in distribution of genotypes (w 2 ¼ 9.46, P ¼ 0.009) and crude OR analysis were highly significant between cases and controls (OR ¼ 3.77, CI ¼ 1.46 -9.77, P ¼ 0.004 for normal vs variant homozygotes, Table 1 ).
Results of logistic regression confirmed that carriers of homozygous genotype NQO1*2/*2 are at high risk of breast cancer (age-adjusted OR ¼ 3.68, CI ¼ 1.41 -9.61, P ¼ 0.008, Table 2 ). Individuals carrying the variant homozygous genotype of NQO1 (*2/*2) lack NQO1 expression. 21 Quinones and their reduced forms, hydroquinones, are mutagens that adduct DNA. 22, 23 The mutational spectra of quinones, semiquinones (intermediates of transitions between oxidized and reduced forms), and hydroquinones differ from each other with respect to their mutational frequency and specificity. NQO1 protects the cells from quinone muta- genicity by competing with one-electron donor P450 reductase, which produces highly reactive semiquinones. 24 Moreover, the frequently used chemotherapy for various tumors by quinone anticancer drugs, anthracyclines (eg doxorubicin, epirubicin), is based on the ability of reduced form to promote apoptosis and bind to DNA -topoisomerase II complex. 25 Carriers of mutant homozygote genotype have no NQO1 activity and thus basic hypothesis regarding these individuals may be drawn: simultaneous lack of the NQO1 activity and exposure to quinones, for example, products of benzene metabolism promotes mutagenesis and carcinogenesis. Further research is needed to confirm or disprove this hypothesis. The role of NQO1 as risk factor in breast cancer has not been proposed so far.
According to our results, GSTM1null and GSTT1null (Tables 1 and 2 ) do not constitute a significant risk factor for breast cancer.
We have noted that the frequency of GSTP1*2/*2 in cases was higher than that in controls (OR ¼ 1.54, CI ¼ 0.86 -2.75, P ¼ 0.145, Table 2 ). Although this difference was not significant, it complies with previous reports on higher frequency of GSTP1*2/*2 allele in breast cancer cases. 26, 27 GSTP1 is involved in a wide range of detoxifying reactions, for example, conjugation of epoxides, dihydrodiols, products of oxidative stress, etc. and effect of variant alleles may be different at each of these reactions. NedelchevaKristensen et al 28 and Gudmundsdottir et al 26 found an association of the GSTP1*2 allele with an increased frequency of loss of heterozygozity and mutations in the p53 locus. Thus, it seems that the variant GSTP1*2 or another possibly linked alteration may contribute to the accumulation of genetic damage during tumor progression and further study is needed to clarify the role of this enzyme in breast cancer.
Analysis of EPHX1 genotypes revealed that carriers of EPHX1*3/*3 genotype are over-represented among breast cancer cases (OR ¼ 1.47, CI ¼ 0.88 -2.43, P ¼ 0.138, Table 2 ). The EPHX1*3 was assigned as low activity allele by functional study undertaken by Hasset et al. 5 Therefore,
we have constructed EPHX1 activity based on combinations of both genotypes in exons 3 and 4. 20 Analysis of distribution of the deduced EPHX1 activity between cases and controls confirmed our hypothesis that carriers of low EPHX1 activity may be at higher risk of breast cancer in comparison with carriers of high EPHX1 activity (ageadjusted OR ¼ 1.60, CI ¼ 0.92 -2.78, Table 3 ). This result was not statistically significant (P ¼ 0.098), but together with the fact that the role of EPHX1 polymorphisms and activity in breast cancer was not studied in detail so far it presents potentially interesting topic for further research.
Analysis of the distribution of combinations of polymorphisms in cases and controls
Combinations of polymorphisms are not frequently studied due to various reasons including small sample size prone to statistical bias and difficult interpretation. We have constructed several potentially interesting combinations based on the principle of prior hypothesis that presence of variant alleles in two genes may increase risk of breast cancer. Genes coding for generally recognized detoxification enzymes (GSTs and EPHX1) known to interact with environmental factors were selected. Results revealed that in combination especially EPHX1, GSTP1, and GSTM1 may represent significant modifiers of breast cancer risk (Table 4) . Subjects with GSTM1null together with at least one variant GSTP1 allele were at significantly higher risk of breast cancer (age-adjusted OR ¼ 2.03, CI ¼ 1.18 -3.50, P ¼ 0.01, Table 4 ). In concert 
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GSTM1 modified the risk of breast cancer also in combination with EPHX1. The combination of variant genotypes of GSTM1null and EPHX1*3/*3 was found as risk factor (age-adjusted OR ¼ 2.15, CI ¼ 1.02 -4.53, P ¼ 0.044; Table 4 ). This result was confirmed by analysis of deduced EPHX1 activity (age-adjusted OR ¼ 1.88, CI ¼ 1.00 -3.52, Numbers of genotype carriers presented (percentages in brackets). EPHX1 activity was deduced according to previously published method 20 from combinations of the following genotypes: EPHX1 (exon 3+exon 4), low: 3/*3 + *1/*1, *3/*3 + *1/*4, *1/*3 + *1/*1, and *3/*3 + *4/*4; medium: *1/*1 + *1/*1, *1/*3 + *1/*4, and *1/*3 + *4/*4; high: *1/*1 + *1/*4, *1/*1 + *4/*4. Table 4 ). EPHX1 metabolizes wide spectra of xenobiotics, for example, ethylene oxide and reactive metabolites of benzene, styrene, and butadiene present in cigarette smoke, engine exhausts, industrial and household sources. It was found that individuals exposed to styrene carrying alleles predisposing to low and medium EPHX1 activity exhibited higher frequencies of chromosomal aberrations than individuals with highactivity alleles. 33 Similar tendency was observed in individuals exposed to butadiene (unpublished data). Thus, we may speculate that highly lipophillic organic solvents as styrene (partition coefficient for fat:blood is 93.8, for lung:blood is 1.46) 34 may accumulate in breast fat and prolong exposure of this tissue to metabolism-related mutagens. Expression of EPHX1 in breast tissue was already reported 35 and there is also a considerable amount of data on styrene genotoxicity. 33 The role of oxidative stress should be noted as well. Breast tissues of patients with the suggested high-activity genotype of GSTP1 (*1/*1) contained lower level of 8-hydroxy-2 0 -deoxyguanosine, marker of oxidative DNA damage when compared with patients carrying the low-activity alleles. 36 Both EPHX1 low activity and GSTP1 variant alleles were associated with higher genotoxicity of styrene-7,8-oxide in vitro (by micronucleus test) in the recently published study of Laffon et al.
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Carriers of both NQO1*2/*2 genotype and low EPHX1 activity prevailed among cases, but due to low numbers in the analyzed groups (Table 4) this result should be taken with caution.
Taken together, our findings seem to suggest an influence of genetic polymorphisms of xenobiotic-metabolizing enzymes, particularly NQO1, on the susceptibility to breast cancer, possibly by change of the ratio of activation/ detoxification of procarcinogens or by linkage to another cancer-causative gene(s). The above-discussed results suggest that EPHX1 may be attractive gene for further study of breast cancer risk. Owing to low numbers of cases in studied groups and the fact that no correction was applied for multiple testing, the study of combinations of genotypes should be considered as exploratory and providing inspiration for focusing further research on risk factors and understanding the molecular mechanisms underlying the development and progression of breast cancer.
